Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA okays Watson's flavored nicotine gum

This article was originally published in The Tan Sheet

Executive Summary

FDA approves Morristown, N.J.-based Watson Laboratories' sale of 2 mg and 4 mg nicotine polacrilex gum coated with fruit and cinnamon flavors. The name brand equivalent Nicorette Fruit Chill and Cinnamon Sugar Coated Gums helped GlaxoSmithKline sell more than $305 million of the gum in the 12 months ending March 29, Watson says in a July 8 release. FDA approved Watson's mint-flavored equivalent of GlaxoSmithKline Consumer Healthcare's Nicorette gum in December 2008 (1"The Tan Sheet" Jan. 5, 2009, In Brief)

You may also be interested in...



Mint nicotine gum approved

FDA approves Dec. 29 Corona, Calif.-based Watson Laboratories' mint-flavored OTC Nicotine Polacrilex gum in 2 mg and 4 mg. The gum is the generic equivalent of GlaxoSmithKline Consumer Healthcare's Nicorette fresh mint gum, and will hit store shelves in early January. More than $300 million of nicotine gum was sold in the 12 months ending September 2008, according to Information Resources Inc. sales data

Industry Self-Regulation Group’s Knowledge Of Drug Types Questioned By US Homeopathic Firm

Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.

Novartis Takes Huntington's Path With SMA Therapy Branaplam

With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.

Topics

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel